2026· International review of neurobiology· Vol 191, pp.
91-111
· 0 citations
Medicine
TL;DR
The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.
This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.
M. M. Mir, Gulzar Muzaffar Mir, Abdul Majid et al.· International review of neur...· 0 citations
This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.
Priya, Radhika Mittal, Jyotirmoy Banerjee et al.· International review of neur...· 0 citations
This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinicall...
This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.
Sakshi Kumari, Amaan Rais, Mohd Suhail Ashar et al.· International review of neur...· 0 citations